BCL2 and neoplasm: In line with this, Pham et al. found that the presence of BCL-2 primarily dictates the cellular sensitivity to venetoclax in aggressive DLBCL cell lines, as well as primary aggressive cells and in vivo patient-derived tumor xenograft models 34, suggesting a possible stochiometric effect of venetoclax by BCL-2 expression.